2023
KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
McHenry A, Rottmann D, Buza N, Hui P. KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence. Virchows Archiv 2023, 483: 71-79. PMID: 37219599, DOI: 10.1007/s00428-023-03564-z.Peer-Reviewed Original ResearchConceptsOvarian serous borderline tumorsSerous borderline tumorsNon-invasive implantsDisease-free survivalKRAS mutationsTumor recurrenceExtraovarian implantsAdverse disease-free survivalWorse disease-free survivalHigher stage diseaseKRAS mutation testingHigher tumor stageWild-type KRASBRAF V600E mutationBRAF mutational analysisBorderline tumorsClinical outcomesHistological subtypesTumor stageBRAF mutationsUseful biomarkerInvasive implantsTumors correlatesV600E mutationMutational status
2017
Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis
Snir OL, DeJoseph M, Wong S, Buza N, Hui P. Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis. Modern Pathology 2017, 30: 1467-1475. PMID: 28664933, DOI: 10.1038/modpathol.2017.66.Peer-Reviewed Original ResearchConceptsMixed germ cell tumorGerm cell tumorsPure immature teratomaImmature teratomaCell tumorsMature teratomaGenetic zygosityMixed ovarian germ cell tumorOvarian germ cell tumorsOvarian immature teratomaImmature ovarian teratomaDifferent pathogenetic pathwaysMature cystic teratomaImmature teratoma componentsDifferent biological behaviorTeratoma componentsRate of homozygosityCystic teratomaOvarian teratomaTumor recurrenceCommon cellular originPathogenetic pathwaysGrade 2TumorsTeratoma